-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, researchers examined the long-term health outcomes of offspring of mothers with inflammatory bowel disease (IBD) and assessed the effects of IBD treatment drugs on the health outcomes of future generations.
conducted a multi-center retrospective study in the Netherlands.
between 1999 and 2018, IBD-delivered mothers from 20 hospitals participated.
information on the characteristics of a child's disease, drug use, lifestyle, pregnancy and long-term health outcomes is collected from the mother's and child's medical records until the child is 5 years of age.
of the study was to assess infection rates, and the secondary endpoint was to assess vaccination, growth, autoimmune diseases and malignant tumor events.
626 women and 1,000 children with IBD participated in the study, 381 had Crohn's disease (CD, 61%), 225 had ulcerative colitis (UC, 36%) and 20 had unclassified IBD (3%).
196 (20 per cent) the mothers of newborns received anti-tumor necrotoxytic drugs during pregnancy, 240 cases of thiopental monotherapy (24 per cent), 60 other drugs were received simultaneously in thiopental, and 564 mothers of newborns did not receive anti-tumor necrotum cause drugs and or thiopental (as a control group) during pregnancy.
study found that exposure to in-house IBD drugs was not associated with poor long-term health outcomes in future generations.
use of thiopental during pregnancy leads to an increase in bile siltation (ICP) in the maternal liver, but does not affect birth outcomes and long-term health outcomes in children.
study concluded that for pregnant women with inflammatory bowel disease, receiving anti-inflammatory bowel disease medication during pregnancy does not lead to abnormal health in future generations.
.